Krishna Institute of Medical Sciences profit and loss

Latest FY26

Revenue: ₹3,905cr+28.6% on FY25
EBITDA: ₹802cr+2.4% on FY25
Net profit: ₹242cr−41.7% on FY25
EPS: ₹6.03−37.3% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	4,213	3,905	3,035	2,498	2,198	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	35.5	26.2	31.9	13.1	25.9
	4,248	3,931	3,067	2,511	2,224
	911	842	640	537	474
	−41.4	−32.9	−13.5	−6.6	6.2
	743	682	500	422	346
	253	203	90.3	47.0	30.5
	331	283	177	147	129
	1,767	1,612	1,126	905	767
	3,964	3,588	2,520	2,051	1,753
	833	802	783	640	604
	502	519	606	494	475
Profit
	284	343	547	460	470
	−11.2	−11.2	10.8	0.0	14.8
	273	331	558	460	485
	139	136	150	120	117
	−57.0	−44.3	−6.2	4.0	2.5
	82.4	91.9	143	124	119
	3.6	2.6	0.0	−0.3	0.0
	194	242	415	336	366
	191	239	415	336	366
	0.7	0.2	−2.3	0.3	0.9
	195	242	413	336	367
	205	241	385	310	336
	−9.8	0.6	30.3	25.9	29.5
Per share
	₹5.10	₹6.03	₹9.61	₹38.75	₹42.03
	₹5.10	₹6.03	₹9.61	₹38.75	₹42.03
Other comprehensive income — detail
	0.7	0.2	−2.3	—	—
	−0.8	−0.2	3.1	—	—
	—	—	—	−0.4	−1.2
	0.1	0.0	−0.8	—	—
	—	—	—	0.1	0.3
	205	242	383	310	337
	−9.6	0.7	30.0	25.9	29.5
Per share — as-filed variants
	₹5.10	₹6.03	₹9.61	₹38.75	₹42.03
	₹5.10	₹6.03	₹9.61	₹38.75	₹42.03
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	3,343	3,096	2,408	1,968	1,717
	79.4%	79.3%	79.3%	78.8%	78.1%
Adjusted (ex-exceptional items) — derived
	284	343	547	460	470
	−11.2	−11.2	10.8	0.0	14.8
	202	250	407	336	355
	₹5.31	₹6.23	₹9.42	₹38.75	₹40.74

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

KIMS₹704.60

Krishna Institute of Medical Sciences Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersAPOLLOHOSP MAXHEALTH FORTIS JUBLPHARMA INDGN ONESOURCE PFIZER POLYMEDMcap ₹28,184 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	2,197.7	2,498.1	3,035.1	3,904.6	4,212.5
Other Income	25.9	13.1	31.9	26.2	35.5
Total Income	2,223.6	2,511.2	3,067.0	3,930.8	4,248.0
Expenses
+ Purchases of Stock-in-Trade	474.5	536.9	640.4	841.8	911.0
+ Changes in Inventories	6.2	-6.6	-13.5	-32.9	-41.4
+ Employee Benefit Expense	346.4	422.4	499.5	681.7	743.3
+ Finance Costs	30.5	47.0	90.3	202.5	253.3
+ Depreciation & Amortisation	129.3	146.5	177.2	283.2	330.6
+ Other Expenses	766.6	905.1	1,125.8	1,612.0	1,766.8
Total Expenses	1,753.5	2,051.3	2,519.7	3,588.3	3,963.6
EBITDA	604.0	640.4	782.9	802.0	832.8
EBIT	474.8	493.9	605.7	518.8	502.2
Profit
PBT before Exceptional Items	470.1	459.9	547.3	342.5	284.4
+ Exceptional Items	14.8	0.0	10.8	-11.2	-11.2
Pretax Income	484.9	459.9	558.1	331.3	273.2
+ Current Tax	116.6	119.6	149.5	136.2	139.4
+ Deferred Tax	2.5	4.0	-6.2	-44.3	-57.0
Tax Expense	119.1	123.6	143.3	91.9	82.4
+ Share of Associates & JVs	0.0	-0.3	0.0	2.6	3.6
Net Income	365.8	336.0	414.8	242.0	194.4
+ Net Income — Continuing Ops	365.8	336.3	414.8	239.4	190.8
+ Other Comprehensive Income	0.9	0.3	-2.3	0.2	0.7
Total Comprehensive Income	366.7	336.3	412.5	242.2	195.1
Net Income to Common	336.3	310.1	384.5	241.4	204.5
Minority Interest	29.5	25.9	30.3	0.6	-9.8
Per Share
Basic EPS	42.03	38.75	9.61	6.03	5.10
Diluted EPS	42.03	38.75	9.61	6.03	5.10
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-2.3	0.2	0.7
+ Tax on Items NOT to be Reclassified	—	—	3.1	-0.2	-0.8
+ Tax on Items NOT to be Reclassified — alt tag	-1.2	-0.4	—	—	—
+ Tax on Items to be Reclassified	—	—	-0.8	0.0	0.1
+ Tax on Items to be Reclassified — alt tag	0.3	0.1	—	—	—
Comprehensive Income — Owners of Parent	337.1	310.4	382.5	241.5	205.0
Comprehensive Income — Non-controlling Interests	29.5	25.9	30.0	0.7	-9.6
Per Share — as-filed variants
Basic EPS — Continuing Operations	42.03	38.75	9.61	6.03	5.10
Diluted EPS — Continuing Operations	42.03	38.75	9.61	6.03	5.10
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,717.0	1,967.9	2,408.2	3,095.7	3,342.9
Gross Margin %	78.13	78.77	79.34	79.28	79.36
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	470.1	459.9	547.3	342.5	284.4
− Exceptional Items (reconciliation)	14.8	0.0	10.8	-11.2	-11.2
Net Income Adj (tax-effected)	354.6	336.0	406.8	250.1	202.2
EPS Adj	40.74	38.75	9.42	6.23	5.31
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	2.00	2.00	2.00
Paid Up Equity Capital	80.0	80.0	80.0	80.0	84.0

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.